Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | LTA4H | P09960 | 6/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | AKT2 | P31751 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20249111 | 0.89 | S1PR5 (0.51) | ALDH1A1KMT2AHRH3LTA4HKCNH2 | |
| SCHEMBL20255310 | 0.85 | LTA4H (0.48) | ALDH1A1KMT2ALTA4H | |
| SCHEMBL20249155 | 0.84 | S1PR5 (0.54) | KMT2ALTA4H | |
| SCHEMBL18291590 | 0.83 | ALDH1A1 (0.56) | ALDH1A1KDM4ENPC1RAB9AKMT2A | |
| SCHEMBL20249121 | 0.83 | ALDH1A1 (0.52) | ALDH1A1KDM4ENPC1RAB9AKMT2A | |
| SCHEMBL20249406 | 0.82 | PPARD (0.47) | ALDH1A1KMT2AKCNH2GPR119 | |
| SCHEMBL18291424 | 0.82 | KDM4E (0.54) | ALDH1A1KDM4ENPC1RAB9AKMT2A | |
| SCHEMBL20255165 | 0.82 | ALDH1A1 (0.47) | ALDH1A1KMT2AKCNH2GPR119 | |
| SCHEMBL20249249 | 0.81 | PPARD (0.43) | KMT2AHRH3LTA4HKCNH2GPR119 | |
| SCHEMBL20249125 | 0.81 | HRH3 (0.45) | KMT2AHRH3LTA4HKCNH2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | ALDH1A1 944/4885KDM4E 470/4885NPC1 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.